Literature DB >> 752296

Carcinoma of the esophagus.

R A Cukingnan, J S Carey.   

Abstract

Carcinoma of the esophagus continues to have a low 5-year cure rate despite advances in radical surgery and super-voltage radiation. Neither patient education nor newer diagnostic techniques have improved survival. The reported operative mortality is 4 to 30% for esophagogastrostomy and 10 to 44% for colon interposition. Average survival time with surgery is 11 to 28 months and 5 to 11 months with irradiation. Local recurrence is high (33 to 76%) with irradiation. The reported 5-year survival rate with preoperative irradiation followed by surgery is higher (14 to 25%). Recent reports have concentrated on improving functional rehabilitation rather than improving cure rates. Palliative surgery is more acceptable because of lowered operative morbidity and mortality and the high complication rate with radiation therapy for far advanced disease. New approaches of interest include fundoplication added to esophagogastrostomy, substernal gastric bypass with anastomosis in the neck, reversed gastric tube (Heimlich operation), the addition of postoperative rather than preoperative irradiation in patients with potentially curable lesions, the use of preoperative hyperalimentation, and the potential application of immunotherapy.

Entities:  

Mesh:

Year:  1978        PMID: 752296     DOI: 10.1016/s0003-4975(10)63684-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Management of panesophageal cancer by blunt resection without thoracotomy and reconstruction with stomach.

Authors:  J W Baker; G L Schechter
Journal:  Ann Surg       Date:  1986-05       Impact factor: 12.969

2.  Cancer of the esophagus. The Cleveland Clinic experience.

Authors:  S Galandiuk; R E Hermann; D M Cosgrove; J J Gassman
Journal:  Ann Surg       Date:  1986-01       Impact factor: 12.969

3.  Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.

Authors:  Elisabeth I Heath; Barbara A Burtness; Lawrence Kleinberg; Ronald R Salem; Stephen C Yang; Richard F Heitmiller; Marcia I Canto; Jonathan P S Knisely; Mark Topazian; Elizabeth Montgomery; Nancy Tsottles; Yazdi Pithavala; Bridget Rohmiller; Mary Collier; Arlene A Forastiere
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

4.  A procedure to elongate the stomach tube in the esophageal replacement.

Authors:  M Kijima; F Nagao; T Ito; M Kosuge; S Iwabuchi; Y Sakaguchi
Journal:  Jpn J Surg       Date:  1984-09

5.  Esophagogastrectomy for carcinoma: current hospital mortality and morbidity rates.

Authors:  F H Ellis; S P Gibb
Journal:  Ann Surg       Date:  1979-12       Impact factor: 12.969

Review 6.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

7.  Computed tomography in carcinoma of esophagus and cardia.

Authors:  G Schneekloth; F Terrier; W A Fuchs
Journal:  Gastrointest Radiol       Date:  1983

8.  Adenocarcinoma of the esophagus.

Authors:  J L Mahoney; R E Condon
Journal:  Ann Surg       Date:  1987-05       Impact factor: 12.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.